12.23.25 -- You're In Charge Of Strategic Sourcing? What's That Actually Mean?

This roundtable weaves together diverse perspectives, providing a multifaceted look at what it will take to create a sustainable path forward in rare disease drug development.

Explore a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.

Learn how a platform streamlines LVV titer measurement, offering a faster and more efficient alternative to traditional methods and addressing key process development challenges.

Computational success is no stand-in for therapeutic readiness. Innovators must learn to discern between models rooted in science and those that speculate.

Focusing on quality, the presenters will discuss the importance of adhering to collection protocols and the real-world effects on treatment outcomes.

Using cells with a pre-engineered TARGATT™ landing pad, we achieve inducible expression within just 4-6 weeks after donor plasmid creation, significantly reducing development time and effort.

Analytical technologies like Droplet Digital PCR (ddPCR) provide a more rapid and robust approach to nucleic acid quantification for better sensitivity, accuracy, and precision in therapeutic development.

Discover a systematic approach to scalable plasmid DNA production using E. coli OneShot Top10, which features DOE-driven optimization and key insights for efficient biomanufacturing success.

To execute complex viral product manufacturing, a service provider needs expertise in adherent cell culture capabilities, cell line productivity, and the intricacies associated with these products.

A unique, scalable, and cost-effective approach to generating AAV viral vectors leverages a high-performing cell line, optimized reagents, and purpose-built technology.

Improved iPBMC manufacturing boosts TIL therapy reliability, safety, and affordability through donor screening, process refinements, and performance-based cell selection.

Scaling up viral vector production can be challenging, and ensuring consistent titers and activity requires careful optimization and technical expertise.

The streamlined AAV transient transfection platform de-risks your path to IND and reduces complexity and timeline for lengthy process and analytical development.

Consider a platform that offers clients a personalized, responsive, and expert-driven approach to process development and manufacturing from early clinical to pivotal supply and commercial launch.

Strengthen your precision medicine strategy by ensuring end-to-end traceability and preparing for the emerging fourth link in regenerative medicine’s chain to meet evolving quality and regulatory demands.

Vial labeling demands precise, high-speed labeling systems to ensure accurate and reliable product identification, particularly in the pharmaceutical industry where safety and compliance are paramount.

Critical to a streamlined process is robust process change management with targeted assessments giving you the desired outcome to reduce deviations, lower cost, and enhance strategy.

Our experts and investment in state-of-the-art development and manufacturing facilities underscore our commitment to advancing programs from the clinic to commercialization.

During this session, we will provide an overview of our capabilities, including our contract testing services, and an update on our current capacity.

Review our technical capabilities and specifications and discover how a partner with fill-finish services designed to take advantage of 100% of the product can guide your product to commercial success.

Codex® HiCap RNA Polymerase delivers enhanced safety, cost-effectiveness, and performance, empowering researchers to unlock the full potential of mRNA therapeutics.

Beyond offering our GMP-compliant iPS cells, we develop superior workflows for gene editing and differentiation to provide competitive platforms to our partners and accelerate their therapeutic programs.